People are doing it. Nothing has been published about it in a human being.
In the last twelve months, eleven separate Reddit threads contain someone describing injecting AHK-Cu themselves, counting each thread once and only where a person says they did it rather than asked about it. Subcutaneous into the thigh, into the abdomen, drawn into the same syringe as a KLOW blend. Daily dosing. Injection site soreness.
Published human studies of injected AHK-Cu: none. Published human studies of AHK-Cu by any route: none.
What exists is one laboratory paper from 2007 on human hair follicles in dishes, and a 1990s patent describing intradermal injection in mice. That is the entire evidence base, and the gap between it and what people are doing is the subject of this page.
Our library records AHK-Cu's route as on the skin or injected under the skin, with no established injected amount. Of the 27 listings we track, 24 are vials.
Is there any research on AHK-Cu?
One laboratory paper, cited constantly and usually for the wrong peptide.
Pyo and colleagues, at Seoul National University, published in Archives of Pharmacal Research in 2007. AHK-Cu is alanyl-histidyl-lysine bound to copper, sold mostly for hair loss and not for skin. They took human hair follicles and grew them in organ culture outside the body, and separately grew dermal papilla cells from human follicles in dishes. They exposed both to AHK-Cu at concentrations between a picomolar and a nanomolar, using an 11% stock solution.
The follicles elongated. The papilla cells proliferated and were protected from programmed cell death.1
Three things that study was not.
It was not a study in people. Follicles in a dish and cells in a dish are not a scalp attached to a person with a blood supply and an immune system.
It was not a study of injection. Nothing was injected into anything. The compound was added to culture medium.
And it was not a study of GHK-Cu, although it is routinely cited as one. Multiple pages attribute Pyo 2007 to GHK-Cu, the better-known copper peptide, when it tested AHK-Cu, which differs at the first amino acid. That misattribution runs in both directions: AHK-Cu gets credit for GHK-Cu's larger literature, and GHK-Cu gets credit for a hair study that was actually about AHK-Cu.
Has AHK-Cu ever been injected in a study?
In mice, in a patent. Not in a journal and not in a person.
A 1990s ProCyte patent on stimulating hair growth with peptide copper complexes contains a worked example titled stimulation of hair growth by intradermal injection of peptide-copper complexes. AHK-Cu in sterile saline was injected intradermally at two sites on clipped mice, in litters receiving a chemotherapy agent, to test whether it maintained follicle viability.2
Two details from that document carry over.
The injections were intradermal, into the skin at the site, not subcutaneous into a thigh. Those are different routes with different purposes, and the forum practice is not what the patent describes.
And the patent records the pH of its preparations. Solutions made by adding copper chloride to AHK came out at 2.14 and 2.91 depending on the ratio.2 Those are the manufacturer's own working figures from a process that is not necessarily how any seller makes it today, but they are the only measured pH values for an AHK-Cu solution we could find anywhere.
Most people are not injecting it
Establish this before the rest, because the headline number is easy to misread.
The same search window turned up more threads describing topical use than injection. Thirteen describe mixing AHK-Cu into a serum or scalp solution, usually in hyaluronic acid, and four describe using it with microneedling or a dermaroller, two of them explicitly applying it to the skin after rolling.
So injection is roughly a third of the documented practice, not the default. The majority are doing the thing that matches the evidence: applying a compound to the scalp, which is where the follicles the study tested actually are.
That ratio matters for how you read the eleven. It is a real and growing practice, not a universal one, and the people doing it are departing from both the published work and from what most other users do.
How are people injecting AHK-Cu?
Now the eleven. The detail matters more than the count.
The reported practice is subcutaneous injection, into the outer thigh or the abdomen, often daily, and frequently in the same syringe as GHK-Cu or a KLOW blend. People report injection site soreness. One account describes drawing a blend first and AHK-Cu second and getting no sting. That is a comparison with GHK-Cu, not a report of nothing happening.
Those reports establish that the practice exists. They tell you nothing about whether it works or what it does. They are not a safety signal and they are not a safety clearance. A forum captures what people chose to post, not what happened to everyone who tried it.
What they do establish is that a compound whose published evidence is laboratory work is being injected, routinely enough to leave a trail.
Why AHK-Cu rather than GHK-Cu?
A fair question with an uncomfortable answer.
The two peptides differ at one amino acid. Our guide to GHK-Cu’s different products separates the cosmetic and injectable versions. GHK-Cu has four decades of research behind it, a recent peer-reviewed review of its coordination chemistry and formulation science, and human topical studies, albeit small and mixed. AHK-Cu has one laboratory paper and a patent.
The reason AHK-Cu is associated with hair specifically is that paper. It is the only study in either compound's literature that tested a copper peptide on human hair follicles and found them elongate. GHK-Cu has no equivalent.
So the compound with far less evidence overall holds the one piece of evidence closest to the thing people want, and that single study is doing an enormous amount of work. Our guide on why most peptides have no human evidence covers how often this shape appears.
That also explains the stacking. Several of the injection reports describe drawing AHK-Cu and GHK-Cu into the same syringe. The implicit reasoning is that one brings the hair study and the other brings the body of research, so taking both covers it. Nothing has tested that combination in anything, and combining them makes any effect or reaction impossible to attribute to either.
Is AHK-Cu sold as an injectable?
Not officially, and effectively yes. The AHK-Cu listings tell the same story as the threads.
Of the 27 AHK-Cu listings we track across 25 sellers, 24 are vials. 2 are sprays and 1 is a topical.3 So the format being sold is overwhelmingly the one you reconstitute and draw from, for a compound whose published evidence is a cell culture study and whose recorded routes include topical and injected use, with no established injected amount.
Sizes cluster at 50, 100 and 200 mg. Two listings are 4,800 mg, a bulk quantity and not a vial anyone injects.
A vial is not an instruction. But a market that sells a topical compound almost exclusively in injectable format is answering a question nobody asked out loud.
Does AHK-Cu work for hair loss?
Nobody can say. Four things are unknown, and they are the four that matter.
Whether it reaches anything. The Pyo study worked at a picomolar to nanomolar concentration directly onto cells in a dish. Nothing establishes what concentration reaches a hair follicle from a subcutaneous injection in a thigh, or whether any reaches it at all.
What dose means here. No human study means no studied dose. Figures circulating online are derived from nothing, and our compound record gives scalp use per product and no established injected amount.
What the copper does. AHK-Cu is a copper peptide, and the questions that apply to GHK-Cu apply here with less behind them: how much of the copper is actually bound, what the loose fraction does in tissue, and what repeated dosing adds to a body's copper load. Our guide on why GHK-Cu burns covers the measurement problem, and AHK-Cu has had less attention than GHK-Cu, not more.
Whether the hair loss claim transfers. The study people cite tested follicles directly. Injecting into a thigh to affect a scalp assumes systemic distribution to the follicle, which nobody has measured for this compound.
If you are going to do it anyway
This page does not tell you how, for the reasons above. Three things are useful regardless.
Combining it in one syringe with another compound makes any reaction impossible to attribute. Our guide on mixing two peptides covers why that matters, and most of the reports describe doing exactly that.
Injection site reactions have a pattern that distinguishes irritation from infection, and our guide on when a reaction means stop and get seen covers the difference.
With no human data, your own record is the only record. What you took, how much, when, and what happened is worth writing down, because nobody else is collecting it.
When to stop and be seen
Standard for any injection, not specific to this.
A reaction that keeps growing after the first hour, or spreads the next day. Warmth, hardness and tenderness increasing over a day or two, the pattern of infection. Hives away from the site, swelling of the lips or face, wheeze or any difficulty breathing. A lump that does not settle within a week.
And for any copper compound taken repeatedly over months, fatigue, abdominal pain or feeling generally unwell is worth mentioning to a doctor along with what you have been taking.
Common questions
Does AHK-Cu work for hair loss?
Unknown. One laboratory study found human hair follicles elongated in a dish when exposed to it, and no human study of any kind has been published. Whether that result transfers to a person, by any route, has not been tested.
Can you inject AHK-Cu?
People do, and eleven Reddit threads in the last twelve months contain firsthand accounts of subcutaneous injection. No human study of injected AHK-Cu has been published, by any route, so there is no evidence about whether it works or what it does.
Is there any human research on AHK-Cu?
No. The study everyone cites, Pyo and colleagues in 2007, used human hair follicles in organ culture and dermal papilla cells in dishes. Nothing was given to a person.
Has AHK-Cu ever been injected in a study?
In mice, in a 1990s patent, intradermally into the skin at the treatment site during chemotherapy. That is a different route from the subcutaneous thigh injections people describe, and mice are not people.
Are most people injecting AHK-Cu or applying it?
Applying it. In the same search window, thirteen threads describe mixing it into a serum or scalp solution and four describe using it with microneedling, against eleven describing injection. So injection is roughly a third of documented use and the majority are applying it to the scalp.
Why would someone use AHK-Cu instead of GHK-Cu?
Because the one study that tested a copper peptide on human hair follicles used AHK-Cu. GHK-Cu has far more research overall and no equivalent hair follicle study, so the compound with less evidence holds the piece closest to what people want.
Is AHK-Cu the same as GHK-Cu?
No. They differ at the first amino acid, alanine against glycine. The distinction matters because the 2007 hair study is frequently cited as GHK-Cu evidence when it tested AHK-Cu, so both compounds are credited with research that belongs to the other.
What dose do people inject?
No studied dose exists, because no human study exists. Figures circulating online are not derived from anything, and our compound record gives scalp use per product and no established injected amount.
Is it sold as an injectable?
Not officially, but effectively. Of the 27 listings we track across 25 sellers, 24 are vials, for a compound whose recorded routes include topical and injected use, with no established injected amount.
Does injecting it reach the hair follicle?
Nobody has measured it. The study people cite applied the compound directly to follicles in a dish at very low concentrations. Whether a thigh injection delivers anything to a scalp follicle is unexamined.
Does it sting like GHK-Cu?
Reports vary, and at least one account describes no sting while drawing it after a blend. The pH figures that exist come from a patent describing solutions at 2.14 and 2.91, which is strongly acidic, but those are a manufacturer's process figures rather than a measurement of anything on sale.
Sources
- Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research 2007;30(7):834-839. PMID 17703734, doi:10.1007/BF02978833. Laboratory study from Seoul National University. Ex vivo human hair follicle organ culture and in vitro culture of human dermal papilla cells, exposed to AHK-Cu at concentrations between 10 to the minus 12 and 10 to the minus 9 molar, from an 11% stock solution. Reports follicle elongation, dermal papilla cell proliferation and anti-apoptotic effects. No human subjects, no injection, and the compound tested is AHK-Cu, not GHK-Cu, despite frequent citation of this paper as GHK-Cu evidence.
- Stimulation of hair growth by peptide copper complexes. US patent 5,538,945 (ProCyte Corporation). patft.uspto.gov. Patent document. Example 16 describes stimulation of hair growth by intradermal injection of peptide-copper complexes, in which AHK:Cu in sterile saline was injected intradermally at two sites on clipped mice receiving the chemotherapy agent cytosine arabinoside, with saline-only controls. The document also records preparation pH: solutions of AHK with copper(II) chloride measured 2.14 at a 1.1:1 peptide to copper molar ratio and 2.91 at 1:1. These are the patent's own process figures and not a measurement of any product currently on sale.
- Peptide Decoding compound library and vendor price capture, 5 October 2026. peptidedecoding.com/prices. Our own data. Thread counts are from a structured search of Reddit over the twelve months to October 2026, counting each thread once within a use category and only where a person stated they had done the thing rather than asked about it: 13 threads describing mixing AHK-Cu into a serum or scalp solution, 4 describing use with microneedling or a dermaroller, and 11 describing injection. Listing counts come from the vendor price capture of 5 October 2026, counting one priced product at one seller as a listing. AHK-Cu appears in 27 listings across 25 sellers: 24 vials, 2 sprays and 1 topical. Stated sizes cluster at 50, 100 and 200 mg, with two bulk listings at 4,800 mg. The compound record lists on-skin and injected routes, scalp use per product, and no established injected amount.
Citing this page. Peptide Decoding. Can You Inject AHK-Cu? Listing data from the 5 October 2026 capture. https://peptidedecoding.com/guides/ahk-cu-injection